Logo

AstraZeneca’s Lynparza Plus Imfinzi Receives the EC’s Approval to Treat Endometrial Cancer

Share this
AstraZeneca

AstraZeneca’s Lynparza Plus Imfinzi Receives the EC’s Approval to Treat Endometrial Cancer

Shots:

  • Following the CHMP’s positive opinion, the EC has approved Imfinzi + CT followed by Lynparza with Imfinzi and Imfinzi alone as a 1L treatment of pMMR & dMMR disease, respectively, based on P-III (DUO-E) study assessing the combination vs CT in patients (n=699) with advanced/recurrent endometrial cancer
  • Study showed reduced disease progression or death risk by 43% (mPFS: 15mos. vs 9.7mos.) pMMR disease population and by 58% (mPFS: not reached vs 7mos.) in dMMR disease population. Data was published in Journal of Clinical Oncology
  • Further submissions are being reviewed across Japan & other regions for the same. It is approved in the US for dMMR disease

Ref: AstraZeneca | Image: AstraZeneca

Related News:- AstraZeneca’s Lynparza Plus Imfinzi Receives the CHMP’s Positive Opinion for Treating Endometrial Cancer

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com

Click here to­ read the full press release 

Disha Nankani

Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions